Displaying drugs 13876 - 13900 of 15156 in total
INO-3107
Investigational
KB105
Investigational
MK-2225
Investigational
AMP-101
AMP-101 is a gene therapy comprising an adeno-associated virus type 9 (AAV9) vector encoding the human Dok-7 protein. It is under investigation for the treatment of Dok-7-associated myasthenia.
Investigational
VGM-R02b
Investigational
EXOB-001
EXOB-001 consists of extracellular vesicles derived from cultured human umbilical cord mesenchymal stromal cells.
Investigational
DCN-tCRK
DCN-tCRK is a recombinant, multi-functional fusion protein consisting of human decorin fused to the C-terminal vascular homing peptide tCRK.
Investigational
Insulin B-chain vaccine
Investigational
VTX-803
Investigational
LX-1004
Investigational
Iluzanebart
Investigational
OCU400
OCU400 is a novel gene therapy comprising an adeno-associated viral vector expressing human nuclear hormone receptor subfamily 2 group E member 3 (hNR2E3).
Investigational
DB-OTO
Investigational
AD-114
Investigational
CT041
CT041 is an autologous CAR T-cell product candidate against protein Claudin18.2 (CLDN18.2).
Investigational
UX701
Investigational
AXV101
Investigational
OCU410ST
Investigational
ATSN-101
ATSN-101 is a adeno-associated virus serotype 5 encoding human retinal guanylate cyclase 1 gene (AAV5-GUCY2D)
Investigational
TSHA-105
TSHA-105 is an adeno-associated virus serotype 9 (AAV9) vector with an engineered transgene encoding the human SLC13A5 protein.
Investigational
HMI-204
HMI-204 is an adeno-associated virus serotype HSC15 expressing human arylsulfatase A
Investigational
RP-A601
RP-A601 is an adeno-associated virus serotype rhesus 10 vector expressing the human galactocerebrosidase (GALC) gene
Investigational
WU-NK-101
WU-NK-101 is an allogeneic CD3-depleted, CD56-enriched activated natural killer-cell product
Investigational
Displaying drugs 13876 - 13900 of 15156 in total